NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 08 01:56PM ET
8.21
Dollar change
+0.20
Percentage change
2.54
%
Index- P/E- EPS (ttm)-3.80 Insider Own33.80% Shs Outstand10.50M Perf Week-3.58%
Market Cap107.01M Forward P/E- EPS next Y-1.01 Insider Trans0.00% Shs Float8.63M Perf Month0.00%
Enterprise Value53.86M PEG- EPS next Q-0.71 Inst Own6.17% Short Float0.38% Perf Quarter117.77%
Income-48.13M P/S2.58 EPS this Y23.01% Inst Trans0.70% Short Ratio0.73 Perf Half Y40.82%
Sales41.52M P/B0.62 EPS next Y62.73% ROA-21.52% Short Interest0.03M Perf YTD41.55%
Book/sh13.32 P/C1.83 EPS next 5Y- ROE-26.74% 52W High11.99 -31.53% Perf Year34.59%
Cash/sh4.49 P/FCF- EPS past 3/5Y36.93% - ROIC-29.45% 52W Low3.09 165.29% Perf 3Y-86.52%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-51.94% - Gross Margin56.71% Volatility8.04% 14.23% Perf 5Y-
Dividend TTM- EV/Sales1.30 EPS Y/Y TTM30.70% Oper. Margin-125.06% ATR (14)0.96 Perf 10Y-
Dividend Ex-DateFeb 17, 2016 Quick Ratio1.85 Sales Y/Y TTM85.33% Profit Margin-115.91% RSI (14)51.82 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.03 EPS Q/Q-13.92% SMA201.71% Beta0.15 Target Price14.00
Payout- Debt/Eq0.03 Sales Q/Q169.93% SMA5010.06% Rel Volume1.16 Prev Close8.01
Employees285 LT Debt/Eq0.02 EarningsJun 12 BMO SMA20050.52% Avg Volume45.28K Price8.21
IPOJul 16, 2021 Option/ShortNo / Yes EPS/Sales Surpr.0.00% 44.17% Trades Volume36,795 Change2.54%
Date Action Analyst Rating Change Price Target Change
Jan-18-23Initiated Cantor Fitzgerald Overweight $7
Jun-26-25 04:30AM
Jun-18-25 09:10AM
08:51AM
08:45AM
07:50AM
12:15PM Loading…
Jun-13-25 12:15PM
Jun-12-25 08:30AM
Apr-09-25 09:00AM
Mar-18-25 08:30AM
Mar-11-25 08:30AM
Mar-05-25 08:30AM
Feb-11-25 08:30AM
Jan-21-25 08:30AM
Jan-15-25 08:30AM
Dec-19-24 08:30AM
08:30AM Loading…
Dec-06-24 08:30AM
Dec-05-24 08:30AM
Dec-04-24 04:05PM
Nov-27-24 08:30AM
Nov-18-24 06:57AM
06:00AM
Nov-12-24 08:30AM
Oct-30-24 04:15PM
Oct-15-24 08:30AM
Oct-07-24 08:30AM
Aug-19-24 08:30AM
Jul-12-24 06:00AM
Jul-11-24 08:30AM
Jul-01-24 08:30AM
Jun-20-24 06:00AM
02:52PM Loading…
Jun-18-24 02:52PM
08:30AM
Jun-17-24 08:30AM
Apr-01-24 01:53PM
07:30AM
Feb-09-24 09:25AM
Nov-20-23 06:00AM
Nov-01-23 06:00AM
Sep-15-23 07:10AM
Aug-29-23 12:46AM
Jun-30-23 08:00AM
Jun-26-23 09:30AM
Jun-25-23 08:45PM
Jun-05-23 07:20AM
Mar-14-23 08:56AM
Mar-02-23 07:00AM
Feb-02-23 04:01PM
Jan-19-23 05:00AM
Jan-17-23 10:00AM
Jan-10-23 08:05AM
Dec-16-22 06:27AM
Nov-30-22 09:15AM
Nov-10-22 08:00AM
Sep-09-22 11:17AM
Aug-12-22 09:34AM
Aug-08-22 04:45AM
Jul-16-22 08:03AM
Jun-08-22 12:56PM
Jun-06-22 09:55AM
May-23-22 12:00PM
08:46AM
May-19-22 12:15PM
May-18-22 06:30PM
May-17-22 11:00AM
Prenetics Global Limited is a health sciences company, which engages in the provision of early detection, prevention, and treatment of cancer. It operates through following segments: Consumer Health, Prevention and Diagnostics. The Consumer Health segment focuses on IM8 a health and wellness brand which focuses on consumer health products and Europa, a U.S. sports distribution company. The Prevention segment focuses on its CircleDNA and ACT Genomics business units. The CircleDNA business unit uses next-generation sequencing (NGS) technology for consumer deoxyribonucleic acid (DNA) test. The Diagnostics segment focuses on ACT Genomics business unit is involved in genomic profiling of solid tumors. It has a presence in the United States. . The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and is headquartered in Hong Kong.